Who Paid My Doc
Christopher Connelly
Clinical Neurophysiology Concord, NC Medical Doctor
NPI 1457321978 CMS profile 293022
315 Medical Park Dr, Ste 202, Concord, NC 28025
General payments
$431
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Christopher Connelly of Concord, NC is reported in the CMS Open Payments database as having received $431 across 22 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $56 | 2 | |
| 2023 | General | $308 | 16 | |
| 2022 | General | $49 | 3 | |
| 2020 | General | $17 | 1 |
Beside peers
- Christopher Connelly
- Clinical Neurophysiology median
- Middle half of Clinical Neurophysiology
- National median
In program year 2025, general payments to Christopher Connelly were reported at $56. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.
Show as a table
| Year | Christopher Connelly | Clinical Neurophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $306 | $88–$1,636 | $163 |
| 2020 | $17 | $299 | $85–$1,847 | $114 |
| 2021 | $0 | $325 | $96–$2,308 | $132 |
| 2022 | $49 | $395 | $106–$1,957 | $149 |
| 2023 | $308 | $388 | $120–$1,718 | $160 |
| 2024 | $0 | $471 | $137–$1,931 | $164 |
| 2025 | $56 | $435 | $121–$1,917 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 141 drugsPart D claims
10,094
Drug cost
$1,301,369
Branded share of claims
20.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Austedo Deutetrabenazine | Brand | 14 | $211,380 | |
| Vumerity Diroximel Fumarate | Brand | 21 | $174,566 | |
| Ingrezza Valbenazine Tosylate | Brand | 19 | $162,150 | |
| Aimovig Autoinjector Erenumab-Aooe | Brand | 135 | $115,363 | |
| Ubrelvy Ubrogepant | Brand | 43 | $67,122 | |
| Nuplazid Pimavanserin Tartrate | Brand | 13 | $64,383 | |
| Qulipta Atogepant | Brand | 53 | $62,043 | |
| Nurtec Odt Rimegepant Sulfate | Brand | 25 | $51,946 | |
| Emgality Syringe Galcanezumab-Gnlm | Brand | 40 | $37,794 | |
| Savella Milnacipran Hcl | Brand | 51 | $33,200 |
The 10 drugs with the highest cost, of 141 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$68,123
Medicare patients
475
Services billed
923
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 52% | |
| Depression | 37% | |
| Diabetes | 36% | |
| Ischemic heart disease | 29% | |
| Chronic kidney disease | 27% | |
| Alzheimer's or dementia | 22% | |
| Atrial fibrillation | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
22 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Neurophysiology in North Carolina
Muhammad Zafar
Clinical Neurophysiology · Durham, NC
Christa Swisher
Clinical Neurophysiology · Charlotte, NC
James Caress
Clinical Neurophysiology · Winston Salem, NC
Matthew Luedke
Clinical Neurophysiology · Durham, NC
Vishal Mandge
Clinical Neurophysiology · Durham, NC
Adrian Hadiono
Clinical Neurophysiology · Concord, NC
Related records
Clinical Neurophysiology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Neurophysiology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.